Neuralia TMS Specialises in Pharmacogenetic Testing Across Australia
Australia, 24th Mar 2025, – Neuralia TMS, a leader in non-invasive therapeutic treatments, has announced the expansion of its services to include pharmacogenetic testing across Australia. This new offering enables the company to enhance its ability to tailor treatments to the specific needs of individual patients. The integration of pharmacogenetic testing into Neuralia TMS’s service portfolio further advances the company’s personalised approach to mental health and chronic pain management. Pharmacogenetic testing involves analysing an individual’s genetic profile to assess how
Read more